- Home
- CHRS vs RMBI Comparison
CHRS vs RMBI Comparison
Compare CHRS & RMBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- RMBI
- Stock Information
- Founded
- CHRS 2010
- RMBI 1887
- Country
- CHRS United States
- RMBI United States
- Employees
- CHRS N/A
- RMBI N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- RMBI Major Banks
- Sector
- CHRS Health Care
- RMBI Finance
- Exchange
- CHRS Nasdaq
- RMBI Nasdaq
- Market Cap
- CHRS 134.4M
- RMBI 135.1M
- IPO Year
- CHRS 2014
- RMBI 2019
- Fundamental
- Price
- CHRS $1.07
- RMBI $13.13
- Analyst Decision
- CHRS Strong Buy
- RMBI
- Analyst Count
- CHRS 4
- RMBI 0
- Target Price
- CHRS $5.38
- RMBI N/A
- AVG Volume (30 Days)
- CHRS 2.0M
- RMBI 16.6K
- Earning Date
- CHRS 03-12-2025
- RMBI 01-23-2025
- Dividend Yield
- CHRS N/A
- RMBI 4.57%
- EPS Growth
- CHRS N/A
- RMBI 1.10
- EPS
- CHRS N/A
- RMBI 0.92
- Revenue
- CHRS $304,340,000.00
- RMBI $42,915,000.00
- Revenue This Year
- CHRS $2.07
- RMBI N/A
- Revenue Next Year
- CHRS N/A
- RMBI N/A
- P/E Ratio
- CHRS N/A
- RMBI $14.27
- Revenue Growth
- CHRS 44.19
- RMBI 2.81
- 52 Week Low
- CHRS $0.66
- RMBI $10.15
- 52 Week High
- CHRS $2.65
- RMBI $15.15
- Technical
- Relative Strength Index (RSI)
- CHRS 39.03
- RMBI 33.29
- Support Level
- CHRS $1.06
- RMBI $13.90
- Resistance Level
- CHRS $1.16
- RMBI $14.55
- Average True Range (ATR)
- CHRS 0.08
- RMBI 0.36
- MACD
- CHRS 0.00
- RMBI -0.11
- Stochastic Oscillator
- CHRS 5.56
- RMBI 0.00
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About RMBI Richmond Mutual Bancorporation Inc.
Richmond Mutual Bancorp Inc is a United States-based banking company. Its principal business consists of attracting deposits from the general public & brokered deposits and investing those funds predominantly in loans secured by commercial and multi-family real estate, first mortgages on owner-occupied, one-to four-family residences, a variety of consumer loans, direct financing leases, and commercial and industrial loans.